LAURELWOOD: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Laurelwood is a plant. The nut and other plant parts are used to make medicine.

Don't confuse laurelwood (Calophyllum inophyllum) with blue cohosh (Caulophyllum thalictroides).

Laurelwood is used for leprosy, hemorrhoids, scabies, gonorrhea, vaginal infections, and chicken pox. It is also used for viral infections, such as HIV.

Tamanu oil from the nut of laurelwood is used for skin conditions including sunburn, rashes, burns, psoriasis, dermatitis, scratches, skin blemishes, acne, skin allergies, bedsores, rosacea, and hemorrhoids.

How does it work ?

Laurelwood contains compounds that have been tested in the laboratory and seem to be somewhat effective against HIV. However, there isn't enough evidence to know if laurelwood works for medicinal uses in humans.

Uses & Effectiveness

Insufficient Evidence for

A skin condition that causes redness on the face (rosacea).
Acne.
Bedsores.
Burns.
Chicken pox.
Gonorrhea.
Hemorrhoids.
HIV/AIDS.
Itchy skin infection caused by mites (scabies).
Leprosy.
Rashes.
Scaly, itchy skin (psoriasis).
Scratches.
Skin allergies.
Skin blemishes.
Sunburn.
Other conditions.

More evidence is needed to rate the effectiveness of laurelwood for these uses.

Side Effects

When taken by mouth: There isn't enough information to know if laurelwood is safe or what the side effects might be.

When applied to the skin: There isn't enough information to know if laurelwood is safe. Some people might be allergic to tamanu oil, the oil from the nut of laurelwood.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if laurelwood is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Interactions

We currently have no information for LAURELWOOD overview.

Dosing

The appropriate dose of laurelwood depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for laurelwood. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

Major GC, Alarie F, Dore J, et al. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007;85:54-9. View abstract.

Manson JE, Allison MA, Carr JJ, et al. Calcium/vitamin D supplementation and coronary artery calcification. Menopause 2010;17:683-91. View abstract.

Mao PJ, Zhang C, Tang L, et al. Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013 Oct 30;169(2):106-11. View abstract.

Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 2008;52:847-55. View abstract.

Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855-70. View abstract.

McCarron DA, Reusser ME. Are low intakes of calcium and potassium important causes of cardiovascular disease? Am J Hypertens 2001;14:206S-12S.. View abstract.

McCarron DA. Calcium and magnesium nutrition in human hypertension. Ann Intern Med 1983;98:800-5. View abstract.

McGarry KA, Kiel DP. Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture. Postgrad Med 2000;108:79-82,85-88, 91. View abstract.

Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-37. View abstract.

Meyer HE, Smedshaug GB, Kvaavik E, et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002;17:709-15. . View abstract.

Miller GD, Jarvis JK, McBean LD. The importance of meeting calcium needs with foods. J Am Coll Nutr 2001;20:168S-85S. View abstract.

Minihane AM, Fairweather-Tait SJ. Effect of calcium supplementation on daily nonheme-iron absorption and long-term iron status. Am J Clin Nutr 1998;68:96-102. View abstract.

Minne HW, Pfeifer M, Begerow B, et al. Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalization of blood pressure: a prospective, randomized, and double-blind study. Abstracts World Congress on Osteoporosis 2000.

Morvaridzadeh M, Agah S, Alibakhshi P, et al. Effects of Calcium and Vitamin D Co-supplementation on the Lipid Profile: A Systematic Review and Meta-analysis. Clin Ther 2021;43(9):274-296. View abstract.

Moser LR, Smythe MA, Tisdale JE. The use of calcium salts in the prevention and management of verapamil-induced hypotension. Ann Pharmacother 2000;34:622-9. View abstract.

Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. J Am Diet Assoc 1991;91:66-73. View abstract.

Myung SK, Kim HB, Lee YJ, Choi YJ, Oh SW. Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials. Nutrients 2021;13(2):368. View abstract.

Nakagawa Y, Maeda A, Takahashi T, Kaneoka Y. Gastric necrosis because of ingestion of calcium chloride. ACG Case Rep J. 2020;7(8):e00446. View abstract.

National Osteoporosis Foundation. 2010 Clinician's Guide to Prevention and Treatment of Osteoporosis. www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf.

Need AG, Philcox JC, Hartley TF, et al. Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women. Aust N Z J Med 1986;16:341-6. View abstract.

Neumar, R. W., Otto, C. W., Link, M. S., Kronick, S. L., Shuster, M., Callaway, C. W., Kudenchuk, P. J., Ornato, J. P., McNally, B., Silvers, S. M., Passman, R. S., White, R. D., Hess, E. P., Tang, W., Davis, D., Sinz, E., and Morrison, L. J. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122(18 Suppl 3):S729-S767. View abstract.

De Clercq, E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med.Res Rev. 2000;20(5):323-349. View abstract.

Adeyeye, A. Studies on seed oils of Garcinia kola and Calophyllum inophyllum. Journal Of The Science Of Food And Agriculture 1991;57(3):441-442.

Boyer PL, Currens MH, McMahon JB. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1993;67:2412-20. View abstract.

Buckheit RW, White EL, Fliakas-Boltz V, et al. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999;43:1827-34. View abstract.

Currens MJ, Gulakowski RJ, Mariner JM, et al. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996;279:645-51. View abstract.

Currens MJ, Nariner JM, McMahon JB, Boyd MR. Kinetic analysis of inhibition of human immunodeficiency virus type-a reverse transcriptase by calanolide A. J Pharmacol Exp Ther 1996;279:652-61. View abstract.

Hemavathy, J. and Prabhakar, J. V. Lipid composition of Calophyllum inophyllum kernel. Journal Of The American Oil Chemists' Society 1990;67(12):955-957.

Itoigawa, M., Ito, C., Tan, H. T., Kuchide, M., Tokuda, H., Nishino, H., and Furukawa, H. Cancer chemopreventive agents, 4-phenylcoumarins from Calophyllum inophyllum. Cancer Lett. 8-10-2001;169(1):15-19. View abstract.

Laure, F., Herbette, G., Faure, R., Bianchini, J. P., Raharivelomanana, P., and Fogliani, B. Structures of new secofriedelane and friedelane acids from Calophyllum inophyllum of French Polynesia. Magn Reson.Chem 2005;43(1):65-68. View abstract.

Le Coz, C. J. Allergic contact dermatitis from tamanu oil (Calophyllum inophyllum, Calophyllum tacamahaca). Contact Dermatitis 2004;51(4):216-217. View abstract.

Newman RA, Chen W, Madden TL. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus. J Pharm Sci 1998;87:1077-80. View abstract.

Oku, H., Ueda, Y., Iinuma, M., and Ishiguro, K. Inhibitory effects of xanthones from guttiferae plants on PAF-induced hypotension in mice. Planta Med 2005;71(1):90-92. View abstract.

Patil, A. D., Freyer, A. J., Eggleston, D. S., Haltiwanger, R. C., Bean, M. F., Taylor, P. B., Caranfa, M. J., Breen, A. L., Bartus, H. R., Johnson, R. K., and . The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum Linn. J Med Chem 12-24-1993;36(26):4131-4138. View abstract.

Pillai, S. N., Desai, M. V., and Shah, H. M. Antihelminthic properties of Punnakkai Cake (Calophyllum inophyllum). Indian J Mycol Plant Path 1974;4(145):150.

Potti, G. R. and Kurup, P. A. Antibacterial principle of the root bark of Calophyllum inophyllum: isolation and antibacterial activity. Indian J Exp.Biol. 1970;8(1):39-40. View abstract.

Protocol Title: A Phase 1B Dose-Range Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-calaonlide A on surrogate markers in HIV-positive patients with no previous antiretroviral therapy. Protocol ID numbers: FDA 297A.

Reuters Health. Anti-HIV herbal product shows therapeutic potential in phase I trial. November 1, 1999.

Sekino, E., Kumamoto, T., Tanaka, T., Ikeda, T., and Ishikawa, T. Concise synthesis of anti-HIV-1 active (+)-inophyllum B and (+)-calanolide A by application of (-)-quinine-catalyzed intramolecular oxo-Michael addition. J Org Chem 4-16-2004;69(8):2760-2767. View abstract.

Spino, C., Dodier, M., and Sotheeswaran, S. Anti-HIV coumarins from Calophyllum seed oil. Bioorg.Med Chem Lett. 12-15-1998;8(24):3475-3478. View abstract.

Taylor, P. B., Culp, J. S., Debouck, C., Johnson, R. K., Patil, A. D., Woolf, D. J., Brooks, I., and Hertzberg, R. P. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J Biol.Chem 3-4-1994;269(9):6325-6331. View abstract.

Yimdjo, M. C., Azebaze, A. G., Nkengfack, A. E., Meyer, A. M., Bodo, B., and Fomum, Z. T. Antimicrobial and cytotoxic agents from Calophyllum inophyllum. Phytochemistry 2004;65(20):2789-2795. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.